Skip to main content
Erschienen in: International Journal of Hematology 6/2015

01.06.2015 | Case Report

Two cases of concurrent development of essential thrombocythemia with chronic lymphocytic leukemia, one related to clonal B-cell lymphocytosis, tested by array comparative genomic hybridization

verfasst von: Hyunjung Kim, Woori Jang, Soyoung Shin, Joonhong Park, Myungshin Kim, Yonggoo Kim, Kyungja Han, Gun Dong Lee, Heusung Won, Young Jun Yang

Erschienen in: International Journal of Hematology | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

We present two cases of concurrent development of essential thrombocythemia (ET) with chronic lymphocytic leukemia (CLL) and one related to clonal B-cell lymphocytosis (CBL). Both patients were referred for lymphocytosis and thrombocytosis. A bone marrow biopsy revealed infiltration of small, mature lymphocytes and megakaryocytic hyperplasia. Flow cytometric immunophenotyping and immunoglobulin (IG) gene clonality tests revealed clonal B lymphocytes. Both patients were positive for the JAK2 V617F mutation in whole bone marrow aspirate. The JAK2 V617F mutation was present in isolated B lymphocytes of patient 1, but not patient 2. Cytogenetics were normal in both patients. An array comparative genomic hybridization (CGH) analyses of B cells revealed a gain of 4q28.3, which is reported in non-Hodgkin’s lymphoma, in patient 1, and deletion 22q11.22, which is associated with CLL, and a gain of Xp22.31 in patient 2. In both patients, B cells showed no myeloproliferative neoplasm (MPN)-specific genetic abnormalities. These results suggest that different oncogenic mechanisms in each cell lineage may underlie the concurrent development of ET and CLL (or CBL). Array CGH may be helpful in identifying the pathogenic mechanism in cases of concurrent development of lymphoid neoplasm and MPN.
Literatur
1.
Zurück zum Zitat Khojasteh A, Perry MC. Coexistence of diffuse lymphocytic lymphoma and polycythemia vera. South Med J. 1981;74:771–2.PubMedCrossRef Khojasteh A, Perry MC. Coexistence of diffuse lymphocytic lymphoma and polycythemia vera. South Med J. 1981;74:771–2.PubMedCrossRef
2.
Zurück zum Zitat Kodali S, Chen C, Rathnasabapathy C, Wang JC. JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN). Leuk Res. 2009;33:e236–9.PubMedCrossRef Kodali S, Chen C, Rathnasabapathy C, Wang JC. JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN). Leuk Res. 2009;33:e236–9.PubMedCrossRef
3.
Zurück zum Zitat Musolino C, Allegra A, Penna G, Centorrino R, Cuzzola M, D’Angelo A, et al. Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders. Acta Haematol. 2009;122:46–9.PubMedCrossRef Musolino C, Allegra A, Penna G, Centorrino R, Cuzzola M, D’Angelo A, et al. Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders. Acta Haematol. 2009;122:46–9.PubMedCrossRef
4.
Zurück zum Zitat Robak T, Urbanska-Rys H, Gora-Tybor J, Wawrzyniak E, Korycka A, Bartkowiak J, et al. Coexistence of chronic lymphocytic leukemia and essential thrombocythemia. Leuk Lymphoma. 2003;44:1425–31.PubMedCrossRef Robak T, Urbanska-Rys H, Gora-Tybor J, Wawrzyniak E, Korycka A, Bartkowiak J, et al. Coexistence of chronic lymphocytic leukemia and essential thrombocythemia. Leuk Lymphoma. 2003;44:1425–31.PubMedCrossRef
5.
Zurück zum Zitat Hussein K, Brakensiek K, Ballmaier M, Bormann M, Gohring G, Buhr T, et al. B-CLL developing in a patient with PV is not affected by V617F mutation of the Janus kinase 2. Eur J Haematol. 2006;77:539–41.PubMedCrossRef Hussein K, Brakensiek K, Ballmaier M, Bormann M, Gohring G, Buhr T, et al. B-CLL developing in a patient with PV is not affected by V617F mutation of the Janus kinase 2. Eur J Haematol. 2006;77:539–41.PubMedCrossRef
6.
Zurück zum Zitat Lasho TL, Mesa R, Gilliland DG, Tefferi A. Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes. Br J Haematol. 2005;130:797–9.PubMedCrossRef Lasho TL, Mesa R, Gilliland DG, Tefferi A. Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes. Br J Haematol. 2005;130:797–9.PubMedCrossRef
7.
Zurück zum Zitat Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 2005;106:3377–9.PubMedCentralPubMedCrossRef Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 2005;106:3377–9.PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Shin S, Kim AH, Park J, Kim M, Lim J, Kim Y, et al. Analysis of immunoglobulin and T cell receptor gene rearrangement in the bone marrow of lymphoid neoplasia using BIOMED-2 multiplex polymerase chain reaction. Int J Med Sci. 2013;10:1510–7.PubMedCentralPubMedCrossRef Shin S, Kim AH, Park J, Kim M, Lim J, Kim Y, et al. Analysis of immunoglobulin and T cell receptor gene rearrangement in the bone marrow of lymphoid neoplasia using BIOMED-2 multiplex polymerase chain reaction. Int J Med Sci. 2013;10:1510–7.PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Shanafelt TD, Ghia P, Lanasa MC, Landgren O, Rawstron AC. Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. Leukemia. 2010;24:512–20.PubMedCentralPubMedCrossRef Shanafelt TD, Ghia P, Lanasa MC, Landgren O, Rawstron AC. Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. Leukemia. 2010;24:512–20.PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Xochelli A, Kalpadakis C, Gardiner A, Baliakas P, Vassilakopoulos TP, Mould S, et al. Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin: is this a distinct entity? Blood. 2014;123:1199–206.PubMedCrossRef Xochelli A, Kalpadakis C, Gardiner A, Baliakas P, Vassilakopoulos TP, Mould S, et al. Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin: is this a distinct entity? Blood. 2014;123:1199–206.PubMedCrossRef
11.
Zurück zum Zitat Marti GE, Rawstron AC, Ghia P, Hillmen P, Houlston RS, Kay N, et al. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol. 2005;130:325–32.PubMedCrossRef Marti GE, Rawstron AC, Ghia P, Hillmen P, Houlston RS, Kay N, et al. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol. 2005;130:325–32.PubMedCrossRef
12.
Zurück zum Zitat Gabrail NY, Martin TW. Coexistence of essential thrombocythemia and chronic lymphocytic leukemia. Acta Haematol. 1991;85:31–3.PubMedCrossRef Gabrail NY, Martin TW. Coexistence of essential thrombocythemia and chronic lymphocytic leukemia. Acta Haematol. 1991;85:31–3.PubMedCrossRef
13.
Zurück zum Zitat Tabaczewski P, Nadesan S, Lim SH. Zap-70 positive chronic lymphocytic leukemia co-existing with Jak 2 V671F positive essential thrombocythemia: a common defective stem cell? Leuk Res. 2009;33:854–5.PubMedCentralPubMedCrossRef Tabaczewski P, Nadesan S, Lim SH. Zap-70 positive chronic lymphocytic leukemia co-existing with Jak 2 V671F positive essential thrombocythemia: a common defective stem cell? Leuk Res. 2009;33:854–5.PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Bizzaro N. Chronic lymphocytic leukaemia in a patient with essential thrombocythaemia. Clin Lab Haematol. 1998;20:377–9.PubMedCrossRef Bizzaro N. Chronic lymphocytic leukaemia in a patient with essential thrombocythaemia. Clin Lab Haematol. 1998;20:377–9.PubMedCrossRef
15.
Zurück zum Zitat Laurenti L, Tarnani M, Nichele I, Ciolli S, Cortelezzi A, Forconi F, et al. The coexistence of chronic lymphocytic leukemia and myeloproliferative neoplasms: a retrospective multicentric GIMEMA experience. Am J Hematol. 2011;86:1007–12.PubMedCrossRef Laurenti L, Tarnani M, Nichele I, Ciolli S, Cortelezzi A, Forconi F, et al. The coexistence of chronic lymphocytic leukemia and myeloproliferative neoplasms: a retrospective multicentric GIMEMA experience. Am J Hematol. 2011;86:1007–12.PubMedCrossRef
16.
Zurück zum Zitat Lee H, Kim M, Lim J, Kim Y, Han K, Cho BS, et al. Acute myeloid leukemia associated with FGFR1 abnormalities. Int J Hematol. 2013;97:808–12.PubMedCrossRef Lee H, Kim M, Lim J, Kim Y, Han K, Cho BS, et al. Acute myeloid leukemia associated with FGFR1 abnormalities. Int J Hematol. 2013;97:808–12.PubMedCrossRef
17.
Zurück zum Zitat Fraser CR, Wang W, Gomez M, Zhang T, Mathew S, Furman RR, et al. Transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma to interdigitating dendritic cell sarcoma: evidence for transdifferentiation of the lymphoma clone. Am J Clin Pathol. 2009;132:928–39.PubMedCrossRef Fraser CR, Wang W, Gomez M, Zhang T, Mathew S, Furman RR, et al. Transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma to interdigitating dendritic cell sarcoma: evidence for transdifferentiation of the lymphoma clone. Am J Clin Pathol. 2009;132:928–39.PubMedCrossRef
18.
Zurück zum Zitat Perifanis V, Diamantidis MD, Chalvatzi K, Kaloutsi V, Markala D, Voulgaridou V, et al. Concurrent presentation of nodal myeloid sarcoma and bone marrow chronic lymphocytic leukemia/small lymphocytic lymphoma: a unique association. Int J Hematol. 2014;99:508–12.PubMedCrossRef Perifanis V, Diamantidis MD, Chalvatzi K, Kaloutsi V, Markala D, Voulgaridou V, et al. Concurrent presentation of nodal myeloid sarcoma and bone marrow chronic lymphocytic leukemia/small lymphocytic lymphoma: a unique association. Int J Hematol. 2014;99:508–12.PubMedCrossRef
19.
Zurück zum Zitat Luan SL, Boulanger E, Ye H, Chanudet E, Johnson N, Hamoudi RA, et al. Primary effusion lymphoma: genomic profiling revealed amplification of SELPLG and CORO1C encoding for proteins important for cell migration. J Pathol. 2010;222:166–79.PubMedCrossRef Luan SL, Boulanger E, Ye H, Chanudet E, Johnson N, Hamoudi RA, et al. Primary effusion lymphoma: genomic profiling revealed amplification of SELPLG and CORO1C encoding for proteins important for cell migration. J Pathol. 2010;222:166–79.PubMedCrossRef
20.
Zurück zum Zitat Gunn SR, Bolla AR, Barron LL, Gorre ME, Mohammed MS, Bahler DW, et al. Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene. Leuk Res. 2009;33:1276–81.PubMedCrossRef Gunn SR, Bolla AR, Barron LL, Gorre ME, Mohammed MS, Bahler DW, et al. Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene. Leuk Res. 2009;33:1276–81.PubMedCrossRef
21.
Zurück zum Zitat Li F, Shen Y, Kohler U, Sharkey FH, Menon D, Coulleaux L, et al. Interstitial microduplication of Xp22.31: causative of intellectual disability or benign copy number variant? Eur J Med Genet. 2010;53:93–9.PubMedCrossRef Li F, Shen Y, Kohler U, Sharkey FH, Menon D, Coulleaux L, et al. Interstitial microduplication of Xp22.31: causative of intellectual disability or benign copy number variant? Eur J Med Genet. 2010;53:93–9.PubMedCrossRef
22.
Zurück zum Zitat Borze I, Mustjoki S, Juvonen E, Knuutila S. Oligoarray comparative genomic hybridization in polycythemia vera and essential thrombocythemia. Haematologica. 2008;93:1098–100.PubMedCrossRef Borze I, Mustjoki S, Juvonen E, Knuutila S. Oligoarray comparative genomic hybridization in polycythemia vera and essential thrombocythemia. Haematologica. 2008;93:1098–100.PubMedCrossRef
23.
Zurück zum Zitat Herishanu Y, Lishner M, Bomstein Y, Kitay-Cohen Y, Fejgin MD, Gaber E, et al. Comparative genomic hybridization in polycythemia vera and essential thrombocytosis patients. Cancer Genet Cytogenet. 2001;128:154–7.PubMedCrossRef Herishanu Y, Lishner M, Bomstein Y, Kitay-Cohen Y, Fejgin MD, Gaber E, et al. Comparative genomic hybridization in polycythemia vera and essential thrombocytosis patients. Cancer Genet Cytogenet. 2001;128:154–7.PubMedCrossRef
Metadaten
Titel
Two cases of concurrent development of essential thrombocythemia with chronic lymphocytic leukemia, one related to clonal B-cell lymphocytosis, tested by array comparative genomic hybridization
verfasst von
Hyunjung Kim
Woori Jang
Soyoung Shin
Joonhong Park
Myungshin Kim
Yonggoo Kim
Kyungja Han
Gun Dong Lee
Heusung Won
Young Jun Yang
Publikationsdatum
01.06.2015
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 6/2015
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-014-1713-9

Weitere Artikel der Ausgabe 6/2015

International Journal of Hematology 6/2015 Zur Ausgabe

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.